Clinical Trials Logo

Paraganglioma clinical trials

View clinical trials related to Paraganglioma.

Filter by:
  • Approved for marketing  
  • Page 1

NCT ID: NCT02961491 Approved for marketing - Pheochromocytoma Clinical Trials

Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this sub-study is to provide expanded access of AZEDRA (Ultratrace Iobenguane I 131) and to evaluate the safety and tolerability of AZEDRA in subjects with iobenguane-avid malignant and/or recurrent pheochromocytoma/paraganglioma (PPGL).

NCT ID: NCT01377532 Approved for marketing - Pheochromocytoma Clinical Trials

Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma

Start date: n/a
Phase:
Study type: Expanded Access

This is a compassionate use protocol to allow palliative therapy for patients with malignant pheochromocytoma and paragangliomas.